Innate Pharma Partners with Sobi for Lacutamab; $75M Upfront
Innate Pharma SA announced a strategic partnership with Sobi to license lacutamab, an anti-KIR3DL2 antibody for T-cell lymphoma. Under the agreement, Sobi will pay Innate Pharma $75 million upfront, with potential for up to $465 million in future regulatory and commercial milestones, plus tiered double-digit royalties on net sales. This partnership will enable the initiation of the TELLOMAK-3 Phase 3 study, a key step towards accelerated approval for lacutamab in Sézary syndrome. Additionally, Innate Pharma appointed Markus Jensen as its new Chief Medical Officer, effective September 1, 2026.
Key Highlights
- Innate Pharma entered a strategic partnership with Sobi for lacutamab in T-cell lymphoma.
- Sobi will pay Innate Pharma $75 million upfront upon closing of the transaction.
- Innate Pharma is eligible for up to $40 million in near-term development milestones.
- Innate Pharma is eligible for up to $465 million in future regulatory and commercial milestones.
- Innate Pharma will receive tiered double-digit royalties on net sales of lacutamab.
- The partnership enables the initiation of the TELLOMAK-3 Phase 3 study for lacutamab.
- Lacutamab aims for accelerated approval in Sézary syndrome, a subtype of CTCL.
- Markus Jensen was appointed Chief Medical Officer, effective September 1, 2026.
Price Impact
More from IPHA
Innate Pharma: IPH4502 Data Presentation, Lacutamab Trial Update, €96.8M Cash
Innate Pharma to Participate in Bladder Cancer Panel at BTIG Conference
Innate Pharma Completes IPH4502 Phase 1 Enrollment; Positive Early Data